🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Healthcare Sector SEC Filings — March 26, 2026

Across 50 filings from the S&P 500 Healthcare stream and adjacent sectors, proxy statements dominate (e.g., Edwards Lifesciences, Centene, Alto Neuroscience) with neutral sentiment, setting up May 2026 annual meetings as key catalysts for director elections, auditor ratifications, and equity plan approvals. Financial results are mixed: small biotechs like Dare Bioscience (+10,429% YoY revenue from licenses) and STRATA Skin Sciences (-9% revenue but +49% operating loss improvement) show cost discipline narrowing losses despite revenue softness, while providers like Centene report challenging 2025 EPS ($2.08) but guide >$3.00 for 2026 (+40% YoY growth). Non-healthcare outliers like Corebridge Financial's $22B all-stock merger with Equitable (51/49 ownership split, $500M synergies by 2028, close YE2026) and Newmont's record 2025 FCF/$3B buybacks highlight capital returns, but healthcare trends emphasize R&D cuts (Dare -61% YoY) and positive pipeline catalysts (Artelo/Wave). Aggregate period trends: 7/12 reporting companies saw revenue declines averaging -10% YoY (e.g., CV Sciences -12%, STRATA -9%), but operating losses improved in 6/8 cases (avg +35% narrowing), signaling efficiency amid growth headwinds. Forward-looking optimism in biotech (e.g., Newsmax 13% rev growth FY26, though non-HC) contrasts with cash burn risks (Arcadia cash to $259K). Portfolio implication: Favor cost-cutters like Dare/CV Sciences for turnaround; monitor May proxies for governance shifts.

33 high priority 17 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 26, 2026

Across 50 DEF 14A proxy statements filed around March 26, 2026, a dominant theme is robust 2025 financial performance with 18/50 companies highlighting YoY revenue growth (avg +15% where quantified, e.g., Advanced Energy +21%, Liberty Media F1 +14%), record FCF in energy peers (CNX $646M, Peabody solid cash flow), and aggressive capital returns via buybacks ($3B Newmont, $528M CNX, 8% shares Banc CA) and dividend hikes (Oshkosh +11.8%, Hanover +5.6%). Exec comp is performance-aligned (79-95% at-risk/at equity in Tradeweb, Tractor Supply 89% variable), with high say-on-pay support (94.2% Eastern Bankshares, but KLX only 44.9%). Mixed signals in healthcare (Centene adj EPS $2.08 below outlook but 2026 >$3.00 +40% growth) and industrials (Oshkosh revenue -2.9% YoY). Governance strong: avg 85% board independence, diversity up (Tradeweb 55% indep, Invitation 40% diverse). No widespread insider selling noted; buybacks signal conviction. Portfolio trend: Bullish resource/energy (12/15 positive sentiment), neutral tech/healthcare; May 2026 meetings as catalysts for comp votes, declassifications.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 26, 2026

The IPO Pipeline stream shows heightened activity with two newly published SPAC-related filings (Maywood Acquisition Corp. 2 S-1 and Digital Asset Acquisition Corp. S-4) and one operating company IPO (CIMG Inc. S-1), all filed March 25-26, 2026, signaling a potential resurgence in SPAC and traditional IPO markets amid neutral sentiment across the board. Period-over-period data highlights SPAC IPO completions (e.g., Digital Asset's April 30, 2025 IPO) and CIMG's FY2025 financials with Q4 FY2025 trends, but lacks explicit YoY/QoQ growth numbers, focusing instead on structural setups like founder shares and concentrations. Key developments include Maywood's 10M unit IPO structure with 35% founder ownership post-offering, Digital Asset's de-SPAC with Old Glory (agreement Jan 13, 2026), and CIMG's acquisitions (e.g., Braincon Sep 23, 2025) amid customer/supplier concentrations. Portfolio-level patterns reveal standard SPAC dilution risks (founder shares at ~$0.01) and operating co risks from China/North America revenue splits, implying selective opportunities in monitoring IPO progressions. Market implications point to building catalyst calendars around S-1 effectiveness, business combinations, and warrant exercises, with high materiality (9-10/10) underscoring actionable intelligence for early positioning.

3 high priority 3 total filings
· daily

Global High-Priority Regulatory Events — March 26, 2026

Across 50 US SEC filings dated March 26, 2026, focused on global high-priority events, a mixed sentiment prevails with 18 mixed, 8 positive, 7 neutral, and 3 negative, highlighting financial distress (1 bankruptcy, multiple debt restructurings/amendments) juxtaposed against opportunistic financings and narrowing losses in biotechs/small caps. Period-over-period trends show revenue divergence: 12/25 quantifiable 10-K/10-Qs reported YoY declines averaging -7.5% (e.g., Lands' End -2%, NORTECH -7.6%, VirTra -15%), while 13 showed growth averaging +72% (e.g., AmpliTech +165%, Nyxoah +122%, Spero +39%), with margins expanding in 8/15 cases (avg +210 bps, e.g., Lands' End +80 bps, NORTECH +210 bps). Biotech/pharma cluster (10 filings) averaged net loss narrowing 25% YoY amid R&D cuts, but cash burns persisted; retail/apparel saw uniform sales drops (-2% to -5.6%). Capital allocation leans defensive (dividend hikes in Shoe Carnival +11%, Lands' End implied stability; Newmont $3B buybacks), with forward catalysts clustering in May 2026 proxy votes (15+ meetings) and debt/acquisition milestones (Keurig JDE Peet's by Feb 2027). Critical implications: imminent liquidation risks (Broad Street Realty), dilution threats (Sadbhav MRA equity conversions, Wytec warrants), but alpha in turnaround plays (Spero swung to profit) and growth outliers (Paychex +19.8% revenue). Portfolio pattern: monitor small-cap distress vs. large-cap stability for relative outperformance.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — March 26, 2026

Two US-listed companies, FiscalNote Holdings (NOTE) and Cambium Networks (CMBM), faced delisting notices on March 25, 2026, triggering immediate or imminent trading suspensions due to failure to meet exchange listing rules—low average share price for NOTE (below $1.00 over 30 trading days) and non-compliance with prior Nasdaq decision for CMBM. Trading for NOTE (common and warrants NOTE.WS) suspended immediately on NYSE, shifting to OTC Markets on March 26, 2026; CMBM suspension effective March 27 open on Nasdaq, moving to OTCID. No enriched period-over-period financial trends, insider activity, capital allocation, or forward-looking guidance provided in filings, limiting quantitative comparisons, but both exhibit negative sentiment (10/10 materiality) with potential material adverse effects on share price and liquidity. Overarching theme: heightened regulatory pressure on low-priced small-cap stocks, signaling portfolio-level risks in compliance-challenged names. Investors face immediate liquidity and valuation risks, with appeals possible but uncertain outcomes; no impact on operations or SEC reporting noted.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 26, 2026

Across 31 filings in the USA Corporate Distress & Bankruptcy stream, dominant themes include aggressive liquidity management through debt amendments/extensions (e.g., WYTEC, Profusa, Diameter Credit), equity raises (Health In Tech $7M PIPE, SmartKem $2.6M), and new credit facilities (Stone Point $250M revolver, Masco $1B), signaling ongoing distress but proactive refinancing amid high interest rates. Outright distress peaks with Broad Street Realty's Chapter 7 bankruptcy liquidation and delistings for FiscalNote (NYSE to OTC) and Cambium Networks (Nasdaq suspension March 27, 2026), while reverse splits (Advantage Solutions 1:25) highlight share price pressures. Period-over-period trends show mixed resilience: Synchrony Card portfolio payment rates up to 24.29% monthly avg in 2026 vs 23.47% in 2025 with 95.1% current accounts; MeiraGTx service revenue -81% YoY but net loss improved 23% to $114.2M. Positive M&A catalysts like OLAPLEX $1.4B sale (55% premium), SSR Mining $1.5B asset sale (Q3 2026 close), and Equitable-Corebridge $22B merger (10% EPS accretion by 2028) offer deleveraging paths. Capital allocation leans toward debt reduction/repayment (Wolfspeed $475.9M refinancing saves $62M annual interest), with no major dividend cuts but dilution risks from warrants/equity. Overall, 7/31 filings indicate severe distress (bankruptcy/delistings), but 15+ show financing successes, implying selective opportunities in refinancings vs high bankruptcy risk in microcaps.

31 high priority 31 total filings
· daily

US Executive Officer Management Changes SEC — March 26, 2026

Across 43 filings on USA executive and director changes from March 26, 2026, the dominant theme is leadership transitions with 22 appointments (experienced hires in energy, tech, banking) versus 18 resignations/departures, mostly neutral sentiment but positive on strategic hires like Vitesse Energy's new CEO and Bloom Energy's CFO. Period-over-period data limited but notable: Interlink Electronics Q4 2025 revenue -4.5% YoY to $2.853M, gross margin -790 bps to 31.7%, though FY revenue +1.8% to $11.89M with net loss improved -19% to -$1.615M. No widespread insider trading or capital allocation shifts, but compensation enhancements (e.g., Meritage Homes CEO target $4M cash +$6M equity, Alight TVR awards up to 8.25M shares) signal retention focus. Positive hires boost conviction in growth sectors like AI/energy (Bloom, 3D Systems), while sudden CFO exits (RetinalGenix, MetroCity) flag risks. Portfolio implication: Monitor energy/utilities (6 filings) for stability, tech/biotech (12 filings) for innovation acceleration; overall neutral-to-positive for long-term value via succession planning.

43 high priority 43 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 26, 2026

Broad Street Realty, Inc., the sole filing in this USA Bankruptcy & Insolvency stream, voluntarily petitioned for Chapter 7 bankruptcy on March 20, 2026, in the U.S. Bankruptcy Court for the District of Delaware (Case No. 26-10398-KBO), signaling total liquidation and cessation as a going concern. George L. Miller was appointed Chapter 7 Trustee to oversee asset liquidation and creditor payments, immediately stripping the Board of Directors and executives of all authority. CFO Alexander Topchy resigned effective the same date, underscoring acute management distress amid the collapse. No period-over-period financial trends or forward-looking guidance are viable post-filing, as operations end; sentiment is uniformly negative with 10/10 materiality. This development implies imminent equity wipeout, with portfolio implications for real estate exposure: delisting likely, zero recovery for shareholders. Overarching theme: isolated but extreme insolvency event highlights vulnerability in commercial realty amid presumed prior deteriorating metrics like rising debt or occupancy declines.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 26, 2026

Across 43 filings on USA Board Room Changes from March 26, 2026, the dominant theme is elevated C-suite and board turnover, with 18 CFO/CAO/Principal Accounting Officer changes (e.g., retirements, resignations, appointments), 12 CEO/President shifts, and 15+ board director additions/resignations/not standing for re-election, signaling proactive refreshes amid strategic pivots. Positive sentiment prevails in 12 cases (e.g., experienced hires in energy/tech like Vitesse CEO Jamie Benard, Bloom CFO Simon Edwards), neutral in 26, negative/mixed in 5, with materiality averaging 6/10 and peaking at 9/10 for Vitesse, Apimeds dispute, Skywater transaction. Sparse period-over-period data shows Interlink Electronics Q4 2025 revenue -4.5% YoY ($2.853M vs $2.986M), FY +1.8% ($11.89M), gross margins -780bps Q4/-260bps FY, highlighting product mix pressures; no broad deteriorating trends but isolated losses improving FY net loss -18.6% YoY. Forward-looking catalysts cluster around May 2026 AGMs (Macy's May 15, Auburn May 12) and Q2 transitions (Vitesse May 1 CEO). Portfolio implications: Bullish for leadership upgrades in growth sectors (energy, tech), bearish execution risks in finance CFO churn; monitor for insider conviction via post-change trading.

43 high priority 43 total filings
· daily

US Merger & Acquisition SEC Filings — March 26, 2026

The 8 filings highlight intense SPAC maneuvering amid M&A completions in niche sectors like crypto blockchain and industrial/pharma mergers, with 5/8 filings from blank-check companies (Soulpower, Launch One, Haymaker, IB, Metal Sky) showing extension efforts, financings, and governance changes versus 3 actual deal closures (Atlantic, Crypto Co, Enzon). Key trends include heavy SPAC redemptions (e.g., IB's $7.9M outflow leaving $8.2M trust) and sponsor support via notes/preferred stock, signaling prolonged hunts for targets; no broad YoY/QoQ financial trends reported but capital raises average ~$1.25M principal across notes/preferred for working capital/BC. Positive catalysts emerge from Crypto Co's milestone-based IP acquisition with 2026 blockchain launch and Enzon's all-stock merger (45/55 ownership split), boosting interoperability and operational scale. Mixed sentiment prevails (3 neutral, 2 positive, 1 mixed) with materiality skewed high (5/8 at 7-9/10) on deal-related filings, implying near-term volatility in SPACs but alpha in completed M&A. Portfolio-level pattern: SPACs face redemption pressures (1/5 with quantified $7.9M drain) versus accretive deals with no upfront dilution.

8 high priority 8 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 26, 2026

Across 50 overnight SEC filings for March 25-26, 2026, FY2025 results dominate with mixed outcomes: 12/20 major 10-Ks showed revenue growth averaging +12% YoY (e.g., Lumexa +7.8%, Leef Brands +22.1%, TXO Partners +41.8%), but net losses widened in 8/20 cases amid impairments, higher expenses, and debt costs; REITs and BDCs exhibited portfolio stress with yields declining (BlackRock Multifamily 4.5%, AB Private Credit 9.58% vs 10.51%). SPAC/de-SPAC momentum is strong with 8 filings advancing mergers (Suncrete non-redemptions, Enhanced Games IPO path, Xanadu $500M proceeds), signaling M&A alpha in tech/AI/quantum. Capital allocation leans defensive: buybacks (Williams Sonoma $862M, News Corp $1B program), dividends stable, but leverage rose in energy (TXO +85%). Healthcare/imaging outperforms (Lumexa advanced procedures +14.2% Q4 YoY, leverage down to 3.5x), while banks face NIM expansion offset by provisions (United Security ROA - to 1.01%). Delistings (FiscalNote) and restatements (Genie Energy) flag risks; forward catalysts cluster in Q2 (proxies, earnings April-May). Overall, selective bullishness in growth niches amid broad profitability pressure, favoring de-SPACs and reiterated guidance plays pre-open.

35 high priority 15 medium 50 total filings
· daily

Biotech Small-Cap Approvals — March 25, 2026

Four neutral FDA approvals occurred in biotech small-caps from March 19-20, 2026: one original NDA for atomoxetine hydrochloride (MAP77 LLC) and three ANDAs for lidocaine hydrochloride (QUAGEN, VIWIT PHARM) and ephedrine sulfate (FRESENIUS KABI USA), all under standard review with no special designations or indications specified. A key pattern is duplication in lidocaine generics (2/3 ANDAs), signaling supply buildup in mature anesthetic markets. No high-impact innovation; routine events imply modest portfolio gains for sponsors amid commoditization risks.

4 total filings
· daily

New Drug Approvals (Original) — March 25, 2026

FDA approvals from March 19-20 (reported March 25) consist of four neutral original approvals under standard review, with no priority, breakthrough, or other designations—three ANDAs (75%) signaling routine generic entries and one NDA. A concentration of two lidocaine hydrochloride ANDAs (QUAGEN, VIWIT PHARM) on consecutive days highlights potential supply increase and competition in this molecule. Overall, low materiality for portfolios; generics-focused sponsors gain minor portfolio depth amid commoditized markets.

4 total filings
· daily

HHS & Healthcare Contracts Intelligence — March 25, 2026

HHS demonstrates sustained commitment to biodefense and vaccine R&D with $530M obligated across two long-term contracts: Emergent BioSolutions' $422M VIGIV deal (potential $706M ceiling) provides high revenue visibility through 2027-2029. Mount Sinai's $108M influenza research award (potential $151M) supports innovation but caps upside via cost-no-fee terms. Cross-cutting theme of unexercised options (~$328M combined) signals potential upside amid execution risks from extended timelines.

2 total filings
· daily

New Federal Contractors — March 25, 2026

This one-day snapshot of new federal contractor data is dominated by a $2.95B NASA/Caltech JPL contract (68% of total value), signaling sustained but neutral space R&D funding with limited equity upside due to nonprofit status. Four bullish signals highlight $1.13B in HHS health/pharma/IT and DHS/GSA security/IT contracts, offering reliable multi-year revenue to for-profits like Elevance Health, Emergent BioSolutions, Elbit Systems, and Pyramid Systems. Long-duration commitments (avg. end 2027+) provide visibility but concentrate risks in execution and subawards amid $1.3B unoutlayed.

7 total filings
· daily

Significant Contract Modifications ($10M+) — March 25, 2026

HHS dominates with $1.19B across four contracts (28% of total), signaling sustained federal health IT, biopharma, and R&D spending through 2027+. NASA's $2.95B Caltech JPL modification anchors 68% of volume but offers neutral equity impact as a nonprofit. Bullish signals in for-profit IT/services (Elevance, Emergent, ElbitAmerica, Pyramid) highlight $1.13B in reliable revenue ramps, with minimal outlays in newer awards indicating near-term cash flow acceleration.

7 total filings
· daily

Contract Deobligations Alert — March 25, 2026

Deobligations alert reveals $4.34B in major contract obligations dominated by NASA's $2.95B Caltech/JPL award (68% of total), signaling stable space R&D funding through 2028 but neutral equity impact as nonprofit. Four bullish signals ($1.13B total) highlight reliable revenue for Elevance Health, Emergent BioSolutions, ElbitAmerica, and Pyramid Systems in health IT/pharma, surveillance, and HUD IT through 2026-2030. HHS contracts aggregate ~$1.19B with long-term outlays, underscoring healthcare services resilience amid execution risks from firm-fixed pricing and subawards.

7 total filings
· daily

Contract Option Exercises — March 25, 2026

A $4.34B batch of contract option exercises is dominated by a single $2.95B NASA award to Caltech (68% of total), signaling sustained U.S. space R&D funding through 2028 but limited equity upside due to nonprofit status. Four bullish signals ($1.23B total) highlight reliable revenue for for-profit firms in health IT/pharma (Elevance, Emergent) and security/IT (ElbitAmerica, Pyramid), with performance extending to 2030. Long-term visibility tempers execution risks from firm-fixed-price structures and zero-outlay awards, prioritizing HHS/DHS exposure over neutral nonprofits.

7 total filings